Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jun 26:16:1576326.
doi: 10.3389/fimmu.2025.1576326. eCollection 2025.

The prognostic and clinicopathological value of HALP score in non-small cell lung cancer

Qin Li #  1 , Mengqi Chen #  2 , Huaqin Zhao  2 , Jiawei Zeng  1
Affiliations
Meta-Analysis

The prognostic and clinicopathological value of HALP score in non-small cell lung cancer

Qin Li et al. Front Immunol. .

Abstract

Objective: The prognostic role of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in non-small cell lung cancer (NSCLC) has been widely reported, but the results remain controversial. Therefore, we aim to evaluate the prognostic and clinicopathological value of the HALP score in NSCLC through a pooled analysis.

Methods: We conducted a comprehensive literature search of PubMed, Embase, Web of Science, Cochrane Library, and the ClinicalTrials.gov databases in December 2024 to identify studies evaluating the relationship between the pretreatment HALP score and outcomes in NSCLC patients. Eligible studies included patients treated with surgical resection, chemotherapy, or immunotherapy. The HALP score was calculated using peripheral blood levels of hemoglobin, albumin, lymphocytes, and platelets measured before treatment. Data were extracted and analyzed to determine the association of the HALP score with overall survival (OS), disease/progression/recurrence-free survival (DFS/PFS/RFS), and clinicopathological characteristics. Subgroup and sensitivity analyses were performed to ensure the robustness and reliability of the results.

Results: A total of 10 studies involving 7024 patients were included. The results demonstrated that patients with lower pretreatment HALP score had worse OS (hazard ratio [HR] = 1.73, 95% confidence interval [95% CI]: 1.27-2.34, p < 0.001) and DFS/PFS/RFS (HR = 1.86, 95% CI: 1.30-2.64, p < 0.001). The results remained consistent across subgroup analyses based on study characteristics and sensitivity analyses. Additionally, a lower HALP score was significantly associated with age (odds ratio [OR] = 1.43, 95% CI: 1.15-1.78, p = 0.001) and tumor size (OR = 0.54, 95% CI: 0.38-0.76, p < 0.001).

Conclusions: The HALP score is a valuable prognostic biomarker for predicting survival outcomes in NSCLC patients. Its ability to integrate multiple aspects of systemic inflammation and nutritional status makes it a promising tool for improving risk stratification and guiding treatment decisions. Future studies should continue to validate this finding in prospective, multicentre trials.

Keywords: HALP score; NSCLC; biomarker; prognostic; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of literature retrieval strategy.
Figure 2
Figure 2
The association of the HALP score with clinicopathological characteristics. including age (A), gender (B), smoking history (C), tumor size (D), lymph node metastasis (E), and overall staging (F).
Figure 3
Figure 3
The prognostic impact of the HALP score on overall survival (A) and disease/progression/recurrence-free survival (B).
Figure 4
Figure 4
Sensitivity analyses regarding overall survival (A) and disease/progression/recurrence-free survival (B).
Figure 5
Figure 5
Funnel plots for detecting publication bias in terms of overall survival (A, B) and disease/progression/recurrence-free survival (C, D).
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229–63. doi: 10.3322/caac.21834 - DOI - PubMed
    1. Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. (2020) 41:1–24. doi: 10.1016/j.ccm.2019.10.001 - DOI - PubMed
    1. Li Y, Wang N, Huang Y, He S, Bao M, Wen C, et al. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer. Cancer Genet. (2024), 284–285:34-42. doi: 10.1016/j.cancergen.2024.04.001 - DOI - PubMed
    1. Rami-Porta R, Bolejack V, Goldstraw P. The new tumor, node, and metastasis staging system. Semin Respir Crit Care Med. (2011) 32:44–51. doi: 10.1055/s-0031-1272868 - DOI - PubMed
    1. Portale G, Bartolotta P, Azzolina D, Gregori D, Fiscon V. Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis. Langenbeck’s Arch Surg. (2023) 408:85. doi: 10.1007/s00423-023-02786-8 - DOI - PubMed

MeSH terms

LinkOut - more resources